Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Int J Cardiovasc Imaging ; 37(2): 643-649, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32965605

RESUMEN

Cardiac complications are the major cause of mortality in patients with Thalassemia major (TM). Cardiac T2* MRI is currently the gold standard for assessing myocardial iron concentration. The aim of our study was to assess whether any echocardiographic parameter would correlate with these findings in patients well established on chelation therapy. This was a prospective study on patients with TM who are regularly followed in our clinic. Patients had a cardiac MRI and echocardiogram within 2 months of each other. Echo parameters included global longitudinal strain and diastolic function. We also compared these findings with those from a cohort of thalassemia intermedia (TI) and normal controls. A total of 84 patients (mean age 26.3 ± 6.1 years, 42.8% male) with TM were enrolled. All had normal left ventricular ejection fraction and only 8 patients had MRI T2* < 10. As compared to 17 patients with TI and 53 controls, these patients had significantly higher E/E' and lower pulmonary vein s/dd ratio suggesting early diastolic dysfunction. 28 patients fulfilled criteria for diastolic dysfunction even in the presence of normal MRI T2*. Global longitudinal strain (GLS) was significantly lower in the TM group as compared to the TI and controls. We found no correlation between any of the echo findings and the MRI T2*in TM patients. In patients with thalassemia and MRI T2* > 20 ms features of diastolic dysfunction persist even in the presence of normal LV function and normal GLS. This suggests that diastolic function remains abnormal even when myocardial iron concentrations are normal and follow up therefore is essential.


Asunto(s)
Ecocardiografía Doppler , Quelantes del Hierro/uso terapéutico , Imagen por Resonancia Magnética , Volumen Sistólico , Disfunción Ventricular Izquierda/diagnóstico por imagen , Función Ventricular Izquierda , Talasemia beta/tratamiento farmacológico , Adulto , Estudios de Casos y Controles , Estudios Transversales , Diástole , Femenino , Humanos , Masculino , Valor Predictivo de las Pruebas , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento , Disfunción Ventricular Izquierda/etiología , Disfunción Ventricular Izquierda/fisiopatología , Adulto Joven , Talasemia beta/complicaciones , Talasemia beta/diagnóstico
2.
Ann Hematol ; 99(9): 2009-2017, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32556452

RESUMEN

The consequence of regular blood transfusion in patients with thalassemia major (TM) is iron overload. Herein, we report the long-term impact of chelation on liver iron concentration (LIC) and cardiac T2* MR in patients with TM. This is a retrospective cohort study over 10 years of adolescents and adults with TM aged at least 10 years who had their first cardiac T2* MR between September 2006 and February 2007. One-year chelation therapy was considered the unit of analysis. A total of 99 patients were included in this study with a median age of 18 years. The median cardiac T2* MR and LIC at baseline were 19 ms and 11.6 mg/g dw, respectively. During follow-up, 18 patients died and six underwent successful bone marrow transplantation. Factors associated with decreased survival were older age (HR 1.12, p = 0.014) and high risk cardiac T2* (HR 8.04, p = 0.004). The median cardiac T2* and LIC significantly improved over the 10-year follow-up period (p = 0.000011 and 0.00072, respectively). In conclusion, this long-term "real-life" study confirms that low cardiac T2* adversely impacts the overall survival in patients with TM. Higher baseline LIC predicts a larger reduction in LIC, and lower baseline cardiac T2* predicts a larger improvement in T2*.


Asunto(s)
Terapia por Quelación/tendencias , Imagen por Resonancia Cinemagnética/métodos , Talasemia beta/diagnóstico por imagen , Talasemia beta/tratamiento farmacológico , Adolescente , Terapia por Quelación/métodos , Estudios de Cohortes , Deferasirox/uso terapéutico , Deferiprona/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/diagnóstico por imagen , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/mortalidad , Masculino , Estudios Retrospectivos , Tasa de Supervivencia/tendencias , Factores de Tiempo , Adulto Joven , Talasemia beta/mortalidad
3.
Hematology ; 24(1): 183-188, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30453843

RESUMEN

OBJECTIVES: This study aimed to estimate the prevalence of liver fibrosis and assess the risk factors for developing significant liver fibrosis in patients with Thalassemia Major (TM). METHODS: All patients with TM over the age of 10 years were included in the study. RESULTS: A total of 94 eligible patients underwent 2-D SWE. The median age was 26.7 years. The median of the average 5-year serum ferritin (5yrSF) and liver iron concentration (LIC) assessed by MRI T2* were 1326 µg/L and 6.7 mg/g dw, respectively. Hepatitis C and hepatitis B core antibodies were positive in 38% and 1% of the patients respectively. The proportion of patients with significant fibrosis was 60%. Male gender increased the risk of significant fibrosis (Odds ratio of 0.4; p = .0373). Additionally, the 5yrSF (p = .00661), the LIC (p = .0225) and the lowest LIC of the previous 5 years (p = .0211) were significant. In the multivariable logistic regression model, only 5yrSF (p = .0035) and gender (p = .00984) remained significant. CONCLUSIONS: The risk of liver fibrosis is associated with iron overload and gender in patients with TM.


Asunto(s)
Diagnóstico por Imagen de Elasticidad , Sobrecarga de Hierro/diagnóstico por imagen , Cirrosis Hepática/diagnóstico por imagen , Talasemia beta/tratamiento farmacológico , Adulto , Femenino , Humanos , Sobrecarga de Hierro/sangre , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/terapia , Cirrosis Hepática/sangre , Cirrosis Hepática/etiología , Cirrosis Hepática/terapia , Masculino , Factores de Riesgo , Factores Sexuales , Talasemia beta/sangre , Talasemia beta/complicaciones , Talasemia beta/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...